These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38685133)

  • 1. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines.
    Giardina E; Camaño P; Burton-Jones S; Ravenscroft G; Henning F; Magdinier F; van der Stoep N; van der Vliet PJ; Bernard R; Tomaselli PJ; Davis MR; Nishino I; Oflazer P; Race V; Vishnu VY; Williams V; Sobreira CFR; van der Maarel SM; Moore SA; Voermans NC; Lemmers RJLF
    Clin Genet; 2024 Jul; 106(1):13-26. PubMed ID: 38685133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Optical Genome Mapping in Clinical Genetic Testing of Facioscapulohumeral Muscular Dystrophy.
    Kovanda A; Lovrečić L; Rudolf G; Babic Bozovic I; Jaklič H; Leonardis L; Peterlin B
    Genes (Basel); 2023 Nov; 14(12):. PubMed ID: 38136988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Facioscapulohumeral muscular dystrophy type 2].
    Sacconi S; Desnuelle C
    Rev Neurol (Paris); 2013; 169(8-9):564-72. PubMed ID: 23969240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of facioscapulohumeral muscular dystrophy 2.
    de Greef JC; Lemmers RJ; Camaño P; Day JW; Sacconi S; Dunand M; van Engelen BG; Kiuru-Enari S; Padberg GW; Rosa AL; Desnuelle C; Spuler S; Tarnopolsky M; Venance SL; Frants RR; van der Maarel SM; Tawil R
    Neurology; 2010 Oct; 75(17):1548-54. PubMed ID: 20975055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.
    Rieken A; Bossler AD; Mathews KD; Moore SA
    Neurology; 2021 Feb; 96(7):e1054-e1062. PubMed ID: 33443126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and molecular diagnosis of facioscapulohumeral dystrophy type 1 (FSHD1) in 2012].
    Salort-Campana E; Nguyen K; Lévy N; Pouget J; Attarian S
    Rev Neurol (Paris); 2013; 169(8-9):573-82. PubMed ID: 24011979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy.
    Erdmann H; Scharf F; Gehling S; Benet-Pagès A; Jakubiczka S; Becker K; Seipelt M; Kleefeld F; Knop KC; Prott EC; Hiebeler M; Montagnese F; Gläser D; Vorgerd M; Hagenacker T; Walter MC; Reilich P; Neuhann T; Zenker M; Holinski-Feder E; Schoser B; Abicht A
    Brain; 2023 Apr; 146(4):1388-1402. PubMed ID: 36100962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facioscapulohumeral Muscular Dystrophy.
    Statland JM; Tawil R
    Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. PubMed ID: 27922500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facioscapulohumeral muscular dystrophy-Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease.
    Vincenten SCC; Van Der Stoep N; Paulussen ADC; Mul K; Badrising UA; Kriek M; Van Der Heijden OWH; Van Engelen BGM; Voermans NC; De Die-Smulders CEM; Lassche S
    Clin Genet; 2022 Feb; 101(2):149-160. PubMed ID: 34297364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing.
    Jones TI; Yan C; Sapp PC; McKenna-Yasek D; Kang PB; Quinn C; Salameh JS; King OD; Jones PL
    Clin Epigenetics; 2014; 6(1):23. PubMed ID: 25400706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1.
    Larsen M; Rost S; El Hajj N; Ferbert A; Deschauer M; Walter MC; Schoser B; Tacik P; Kress W; Müller CR
    Eur J Hum Genet; 2015 Jun; 23(6):808-16. PubMed ID: 25370034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
    Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
    Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy: Advancement and Challenges.
    Efthymiou S; Lemmers RJLF; Vishnu VY; Dominik N; Perrone B; Facchini S; Vegezzi E; Ravaglia S; Wilson L; van der Vliet PJ; Mishra R; Reyaz A; Ahmad T; Bhatia R; Polke JM; Srivastava MP; Cortese A; Houlden H; van der Maarel SM; Hanna MG; Bugiardini E
    Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype and phenotype analysis of 43 Iranian facioscapulohumeral muscular dystrophy patients; Evidence for anticipation.
    Alavi A; Esmaeili S; Nafissi S; Kahrizi K; Najmabadi H
    Neuromuscul Disord; 2018 Apr; 28(4):303-314. PubMed ID: 29402602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The French National Registry of patients with Facioscapulohumeral muscular dystrophy.
    Guien C; Blandin G; Lahaut P; Sanson B; Nehal K; Rabarimeriarijaona S; Bernard R; Lévy N; Sacconi S; Béroud C
    Orphanet J Rare Dis; 2018 Dec; 13(1):218. PubMed ID: 30514324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FSHD1 and FSHD2 form a disease continuum.
    Sacconi S; Briand-Suleau A; Gros M; Baudoin C; Lemmers RJLF; Rondeau S; Lagha N; Nigumann P; Cambieri C; Puma A; Chapon F; Stojkovic T; Vial C; Bouhour F; Cao M; Pegoraro E; Petiot P; Behin A; Marc B; Eymard B; Echaniz-Laguna A; Laforet P; Salviati L; Jeanpierre M; Cristofari G; van der Maarel SM
    Neurology; 2019 May; 92(19):e2273-e2285. PubMed ID: 30979860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facioscapulohumeral muscular dystrophy.
    Statland J; Tawil R
    Neurol Clin; 2014 Aug; 32(3):721-8, ix. PubMed ID: 25037087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity.
    Sacconi S; Camaño P; de Greef JC; Lemmers RJ; Salviati L; Boileau P; Lopez de Munain Arregui A; van der Maarel SM; Desnuelle C
    J Med Genet; 2012 Jan; 49(1):41-6. PubMed ID: 21984748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy in Patients Clinically Suspected of FSHD Using Optical Genome Mapping.
    Guruju NM; Jump V; Lemmers R; Van Der Maarel S; Liu R; Nallamilli BR; Shenoy S; Chaubey A; Koppikar P; Rose R; Khadilkar S; Hegde M
    Neurol Genet; 2023 Dec; 9(6):e200107. PubMed ID: 38021397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
    Gatica LV; Rosa AL
    Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.